Cardiovascular biomarkers in clinical studies of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 20, Issue 6, 2018, Pages 1350-1360

  Baldassarre, Maria P A ^a,b   Andersen, Andreas ^b   Consoli, Agostino ^a   Knop, Filip K ^b,c,d   Vilsbøll, Tina ^b,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Capital Region   (Denmark)

Author keywords

cardiovascular disease; clinical trial; type 2 diabetes

Indexed keywords

8 HYDROXYGUANINE; 8 ISOPROSTAGLANDIN F2 ALPHA; 8 OXO 7,8 DIHYDROGUANOSINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; TROPONIN T; UNCLASSIFIED DRUG;

CARDIAC STEM CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL STUDY; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HEART INJURY; HUMAN; INCIDENCE; MEDICAL INFORMATION; MEMBRANE MICROPARTICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; TREATMENT PLANNING; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; EVIDENCE BASED MEDICINE; IMMUNOLOGY; METHODOLOGY; PATHOPHYSIOLOGY; RISK; VASCULAR ENDOTHELIUM;

BIOMARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, CARDIOVASCULAR; OXIDATIVE STRESS; RESEARCH DESIGN; RISK;

EID: 85043253545     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13247     Document Type: Review

References (113)

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. https://doi.org/10.1016/S0140-6736(10)60484-9.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
3. FDA. Guidance compliance regulatory information. 2008. https://www.fda.gov/downloads/Drug/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.psd.
4. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-2362. https://doi.org/10.1161/CIRCULATIONAHA.104.482570.
5. Looker HC, Colombo M, Agakov F, et al. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia. 2015;58(6):1363-1371. https://doi.org/10.1007/s00125-015-3535-6.
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. https://doi.org/10.1067/mcp.2001.113989.
7. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of N-terminal pro–B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;170(6):1170-1183. https://doi.org/10.1016/j.ahj.2015.09.010.
8. Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal Pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37(1):295-303.
9. Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014;37(11):2899-2908. https://doi.org/10.2337/dc14-0669.
10. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115(13):356-376. https://doi.org/10.1161/CIRCULATIONAHA.107.182882.
11. Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157(2):160-168. https://doi.org/10.1016/j.ijcard.2011.06.066.
12. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655-663. https://doi.org/10.1056/NEJMoa031994.
13. Gaede P, Hildebrandt P, Hess G, Parving H-H, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia. 2005;48(1):156-163. https://doi.org/10.1007/s00125-004-1607-0.
14. Tarnow L, Gall M-A, Hansen BV, Hovind P, Parving H-H. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006;49(10):2256-2262. https://doi.org/10.1007/s00125-006-0359-4.
15. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. https://doi.org/10.1056/NEJMoa1307684.
16. Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;2115(9):989-998. https://doi.org/10.1001/jamacardio.2016.3030.
17. van der Leeuw J, Beulens JWJ, van Dieren S, et al. Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc. 2016;5(6):e003048. https://doi.org/10.1161/JAHA.115.003048.
18. Ballo P, Betti I, Barchielli A, et al. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. Clin Res Cardiol. 2016;105(5):421-431. https://doi.org/10.1007/s00392-015-0937-x.
19. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840. https://doi.org/10.1016/S0140-6736(07)61303-8.
20. Semenov AG, Katrukha AG. Analytical issues with natriuretic peptides - has this been overly simplified? EJIFCC. 2016;27(3):189-207.
21. Seferian KR, Tamm NN, Semenov AG, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem. 2008;54(5):866-873.
22. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4(3):355-360. https://doi.org/10.1161/CIRCHEARTFAILURE.110.960260.
23. Collin-Chavagnac D, Dehoux M, Schellenberg F, et al. Head-to-head comparison of 10 natriuretic peptide assays. Clin Chem Lab Med. 2015;53(11):1825-1837. https://doi.org/10.1515/cclm-2014-0592.
24. Zugck C, Nelles M, Katus HA, et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med. 2006;44(10):1269-1277. https://doi.org/10.1515/CCLM.2006.215.
25. Resl M, Clodi M, Vila G, et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart. 2016;102(24):1963-1968. https://doi.org/10.1136/heartjnl-2015-308949.
26. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal Pro–B-type natriuretic peptide: analytic considerations. Am J Cardiol. 2008;101(3):S9-S15. https://doi.org/10.1016/j.amjcard.2007.11.013.
27. Boomsma F, Deinum J, van den Meiracker AH. Relationship between natriuretic peptide concentrations in plasma and posture during blood sampling. Clin Chem. 2001;47(5):963–965.
28. Streng AS, de Boer D, van der Velden J, van Dieijen-Visser MP, Wodzig WKWH. Posttranslational modifications of cardiac troponin T: an overview. J Mol Cell Cardiol. 2013;63:47-56. https://doi.org/10.1016/j.yjmcc.2013.07.004.
29. van der Linden N, Klinkenberg LJJ, Bekers O, et al. Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine (Baltimore). 2016;95(52):e5703. https://doi.org/10.1097/MD.0000000000005703.
30. Sze J, Mooney J, Barzi F, Hillis GS, Chow CK. Cardiac troponin and its relationship to cardiovascular outcomes in community populations – A systematic review and meta-analysis. Hear Lung Circ. 2016;25(3):217-228. https://doi.org/10.1016/j.hlc.2015.09.001.
31. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54-61. https://doi.org/10.1373/clinchem.2011.165795.
32. Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374-1382. https://doi.org/10.1161/CIRCULATIONAHA.114.010815.
33. Everett BM, Cook NR, Magnone MC, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation. 2011;123(24):2811-2818. https://doi.org/10.1161/CIRCULATIONAHA.110.009928.
34. Lepojärvi ES, Piira O-P, Kiviniemi AM, et al. Usefulness of highly sensitive troponin as a predictor of short-term outcome in patients with diabetes mellitus and stable coronary artery disease (from the ARTEMIS Study). Am J Cardiol. 2016;117(4):515-521. https://doi.org/10.1016/j.amjcard.2015.11.038.
35. Everett BM, Brooks MM, Vlachos HEA, et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015;373(7):610-620. https://doi.org/10.1056/NEJMoa1415921.
36. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254-261. https://doi.org/10.1373/clinchem.2009.132654.
37. Mueller M, Vafaie M, Biener M, Giannitsis E, Katus HA. Cardiac troponin T. Circ J. 2013;77:1653-1661. https://doi.org/10.1253/circj.CJ-13-0706.
38. Roche. Elecsys® Troponin T high sensitive (TnT-hs). 2017. http://www.cobas.com/home/product/clinical-and-immunochemistry-testing/elecsys-troponin-t-hs-tnt-hs.html. Accessed May 29, 2017.
39. Gore MO, Seliger SL, DeFilippi CR, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63(14):1441-1448. https://doi.org/10.1016/j.jacc.2013.12.032.
40. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27(4):889-894.
41. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions. 1994;42(3–4):159-162.
42. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101(12):1372-1378.
43. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996;76(5):738-742.
44. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772. https://doi.org/10.1161/01.CIR.101.15.1767.
45. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486-1491.
46. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5(4):e78. https://doi.org/10.1371/journal.pmed.0050078.
47. Herder C, Schöttker B, Rothenbacher D, et al. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. 2011;216. https://doi.org/10.1016/j.atherosclerosis.2011.01.041.
48. Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63(3):1115-1123. https://doi.org/10.2337/db12-1625.
49. Ofstad AP, Gullestad L, Orvik E, et al. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol. 2013;12(1):126. https://doi.org/10.1186/1475-2840-12-126.
50. Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z. The predictive value of TNF-α and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol. 2012;49(1):3-7. https://doi.org/10.1007/s00592-010-0198-0.
51. Nielepkowicz-Goździńska A, Fendler W, Robak E, et al. Exhaled cytokines in systemic lupus erythematosus with lung involvement. Pol Arch Med Wewn. 2013;123(4):141-148. http://www.ncbi.nlm.nih.gov/pubmed/23467253. Accessed May 22, 2017.
52. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990;33(5):644-649. https://doi.org/10.1002/art.1780330506.
53. Sundvall P-D, Elm M, Ulleryd P, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr. 2014;14:88. https://doi.org/10.1186/1471-2318-14-88.
54. D Systems. Human ILHS ELISAR&&#x 2010;6 quantikine kit. 2016. https://www.rndsystems.com/products/human-il-6-quantikine-hs-elisa-kit_hs600b. Accessed February 22, 2018.
55. SJC. Accessed MayQuest Diagnostics. Interleukin&#x 2010;6, highly sensitive, ELISA. http://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=34473X&labCode= 29, 2017.
56. Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2008;13(1):59-78. https://doi.org/10.1080/13547500701615017.
57. Riches P, Gooding R, Millar BC, Rowbottom AW. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. J Immunol Methods. 1992;153(1–2):125-131. http://www.ncbi.nlm.nih.gov/pubmed/1517582. Accessed May 22, 2017.
58. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44(1):6-11. https://doi.org/10.1161/01.HYP.0000130484.20501.df.
59. Drakopoulou M, Toutouzas K, Stefanadi E, Tsiamis E, Tousoulis D, Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis. 2009;206(2):335-339. https://doi.org/10.1016/j.atherosclerosis.2009.01.041.
60. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548 http://www.ncbi.nlm.nih.gov/pubmed/21325005. Accessed June 9, 2017.
61. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397-408. https://doi.org/10.1016/j.jacc.2013.05.016.
62. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18(6):471-478.
63. Emerging Risk Factors Collaboration TERF, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140. https://doi.org/10.1016/S0140-6736(09)61717-7.
64. Goff DC, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 2014;63(25, pt B):2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005.
65. Danesh J, Wheeler JG, Hirschfield GM, et al. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397. https://doi.org/10.1056/NEJMoa032804.
66. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217-231. https://doi.org/10.1093/ije/dyn217.
67. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. Diabetes Care. 2006;29(2):329-333. https://doi.org/10.2337/diacare.29.02.06.dc05-1700.
68. Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes. 2009;58(4):926-933. https://doi.org/10.2337/db08-0900.
69. Cardoso CRL, Leite NC, Salles GF. Prognostic importance of C-reactive protein in high cardiovascular risk patients with type 2 diabetes mellitus: the Rio de Janeiro type 2 diabetes cohort study. J Am Heart Assoc. 2016;5(11):e004554. https://doi.org/10.1161/JAHA.116.004554.
70. Scirica BM. Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem. 2017;63(1):186-195. https://doi.org/10.1373/clinchem.2016.255539.
71. Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, et al. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia. 2015;58(7):1494-1502. https://doi.org/10.1007/s00125-015-3586-8.
72. Vashist SK, Venkatesh AG, Marion Schneider E, Beaudoin C, Luppa PB, Luong JHT. Bioanalytical advances in assays for C-reactive protein. Biotechnol Adv. 2016;34(3):272-290. https://doi.org/10.1016/j.biotechadv.2015.12.010.
73. Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62(8):667-676. https://doi.org/10.1016/j.jacc.2013.03.089.
74. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45(12):2136-2141.
75. Lolekha PH, Chittamma A, Roberts WL, Sritara P, Cheepudomwit S, Suriyawongpaisal P. Comparative study of two automated high-sensitivity C-reactive protein methods in a large population. Clin Biochem. 2005;38(1):31-35. https://doi.org/10.1016/j.clinbiochem.2004.09.001.
76. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med. 2005;352(15):1611-1613. https://doi.org/10.1056/NEJM200504143521525.
77. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49(8):1258-1271.
78. Dupuy AM, Badiou S, Descomps B, Cristol JP. Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clin Chem Lab Med. 2003;41(7):948-949. https://doi.org/10.1515/CCLM.2003.144.
79. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol. 2003;10(4):652-657. https://doi.org/10.1128/cdli.10.4.652-657.2003.
80. Doumatey AP, Zhou J, Adeyemo A, Rotimi C. High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum. Clin Biochem. 2014;47(4–5):315-318. https://doi.org/10.1016/j.clinbiochem.2013.12.014.
81. Andreoli R, Manini P, De Palma G, et al. Quantitative determination of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine, 8-oxo-7,8-dihydroguanine, 8-oxo-7,8-dihydroguanosine, and their non-oxidized forms: daily concentration profile in healthy volunteers. Biomarkers. 2010;15(3):221-231. https://doi.org/10.3109/13547500903434501.
82. Broedbaek K, Weimann A, Stovgaard ES, Poulsen HE. Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med. 2011;51(8):1473-1479. https://doi.org/10.1016/j.freeradbiomed.2011.07.007.
83. Broedbaek K, Køster-Rasmussen R, Siersma V, Persson F, Poulsen HE, de Fine Olivarius N. Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients. Redox Biol. 2017;13:363-369. https://doi.org/10.1016/j.redox.2017.06.005.
84. Broedbaek K, Siersma V, Henriksen T, et al. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care. 2011;34(12):2594-2596. https://doi.org/10.2337/dc11-1620.
85. Broedbaek K, Siersma V, Henriksen T, et al. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes. Diabetes Care. 2013;36(3):669–676. http://care.diabetesjournals.org/content/36/3/669.long. Accessed May 8, 2017.
86. Andreoli R, Mutti A, Goldoni M, Manini P, Apostoli P, De Palma G. Reference ranges of urinary biomarkers of oxidized guanine in (2′-deoxy)ribonucleotides and nucleic acids. Free Radic Biol Med. 2011;50(2):254-261. https://doi.org/10.1016/j.freeradbiomed.2010.11.009.
87. Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med. 2012;52(8):1353-1361. https://doi.org/10.1016/j.freeradbiomed.2012.01.009.
88. Matheson A, Willcox MDP, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev. 2010;26(3):150-171. https://doi.org/10.1002/dmrr.1068.
89. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005;25(2):279–286. http://atvb.ahajournals.org/content/25/2/279.long. Accessed August 14, 2017.
90. LeLeiko RM, Vaccari CS, Sola S, et al. Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol. 2009;104(5):638-643. https://doi.org/10.1016/j.amjcard.2009.04.047.
91. Roest M, Voorbij HAM, Van der Schouw YT, Peeters PHM, Teerlink T, Scheffer PG. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol. 2008;2(4):298-303. https://doi.org/10.1016/j.jacl.2008.06.004.
92. Woodward M, Croft KD, Mori TA, et al. Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci. 2009;116(1):53-60. https://doi.org/10.1042/CS20070404.
93. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-1295. https://doi.org/10.1161/CIRCULATIONAHA.106.652859.
94. Burger D, Touyz RM. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens. 2012;6(2):85-99. https://doi.org/10.1016/j.jash.2011.11.003.
95. Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100(7):2666-2672. https://doi.org/10.1210/jc.2015-1687.
96. Fadini GP, Maruyama S, Ozaki T, et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One. 2010;5(7):1-9. https://doi.org/10.1371/journal.pone.0011488.
97. Németh B, Ajtay Z, Hejjel L, et al. The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis. PLoS One. 2017;12(5):e0177493. https://doi.org/10.1371/journal.pone.0177493.
98. Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833. https://doi.org/10.1161/JAHA.115.001833.
99. Ganz T, Wainstein J, Gilad S, Limor R, Boaz M, Stern N. Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2017;33(2):e2836. https://doi.org/10.1002/dmrr.2836.
100. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30(7):1834-1839. https://doi.org/10.2337/dc07-0019.
101. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303(2):131-137. https://doi.org/10.1006/abio.2001.5575.
102. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42(12):1377-1383. https://doi.org/10.1515/CCLM.2004.257.
103. Boulanger CM, Loyer X, Rautou P-E, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14(5):259-272. https://doi.org/10.1038/nrcardio.2017.7.
104. Nozaki T, Sugiyama S, Koga H, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol. 2009;54(7):601-608. https://doi.org/10.1016/j.jacc.2009.05.022.
105. Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;228(2):R57-R71. https://doi.org/10.1530/JOE-15-0201.
106. Sinning J-M, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+microparticles correlate with cardiovascular outcomes. Eur Heart J. 2011;32(16):2034-2041. https://doi.org/10.1093/eurheartj/ehq478.
107. Santilli F, Marchisio M, Lanuti P, Boccatonda A, Miscia S, Davl G. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016;116(2):220-234. https://doi.org/10.1160/TH16-03-0176.
108. Lanuti P, Santilli F, Marchisio M, et al. A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction. J Immunol Methods. 2012;380(1–2):16-22. https://doi.org/10.1016/j.jim.2012.03.007.
109. Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death novelty and significance. Circ Res. 2016;118(12):1930-1939. https://doi.org/10.1161/CIRCRESAHA.116.308366.
110. Lanuti P, Rotta G, Almici C, et al. Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. Cytom Part A. 2016;89(3):259-270. https://doi.org/10.1002/cyto.a.22730.
111. DiPersio JF. Diabetic stem-cell “mobilopathy”. N Engl J Med. 2011;365(26):2536-2538. https://doi.org/10.1056/NEJMcibr1112347.
112. + stem cells in patients with type 2 diabetes. Diabetes Care. 2017;40(1):125-131. https://doi.org/10.2337/dc16-1755.
113. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia. 2010;53(5):821-831. https://doi.org/10.1007/s00125-010-1681-4.